<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Praveen Govender, MB Bch
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marco C Post, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess Mandel, MD, MACP, ATSF, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H358318164">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoidosis is a multisystemic disease of unknown etiology that is characterized pathologically by nonnecrotizing granulomatous inflammation. Sarcoidosis-associated pulmonary hypertension (SAPH) is an increasingly recognized complication of sarcoidosis that is associated with a poor prognosis. Management varies depending on the predominant mechanism involved.
        </p>
        <p>
         This topic will review the management of SAPH. The diagnosis of SAPH and management of other complications of sarcoidosis are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/132051.html" rel="external">
          "Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/91259.html" rel="external">
          "Overview of extrapulmonary manifestations of sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4317.html" rel="external">
          "Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4922.html" rel="external">
          "Clinical manifestations and diagnosis of cardiac sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">
          "Management and prognosis of cardiac sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5586.html" rel="external">
          "Sarcoid myopathy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">
          "Kidney disease in sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">
          "Neurologic sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">
          "Cutaneous manifestations of sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113435.html" rel="external">
          "Sarcoidosis of bone"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13773.html" rel="external">
          "Cutaneous sarcoidosis: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Several societies have provided guidance on the evaluation and management of SAPH including recommendations from the 2020 American Thoracic Society Clinical Practice Guideline [
         <a href="#rid1">
          1
         </a>
         ] and the 2022 World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) [
         <a href="#rid2">
          2
         </a>
         ]. Our recommendations are mostly in keeping with this guidance.
        </p>
        <p class="headingAnchor" id="H64924700">
         <span class="h1">
          REFERRAL TO EXPERT CENTER
         </span>
         <span class="headingEndMark">
          —
         </span>
         We advocate for a multidisciplinary approach at a PH center that involves cardiologists, pulmonologists, and radiologists with experience in both PH and sarcoidosis. Multidisciplinary teams are necessary since the pathogenetic mechanism is often multifactorial and data in patients with SAPH are limited, rendering treatment decisions difficult.
        </p>
        <p>
         All the information collected during the diagnostic evaluation and classification informs the therapeutic approach. These details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/132051.html" rel="external">
          "Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/132051.html" rel="external">
          "Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults", section on 'Postdiagnostic testing and phenotyping'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3617083945">
         <span class="h1">
          GENERAL MEASURES FOR ALL PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with SAPH, we follow the same basic principles of general management as for other patients with non-sarcoidosis-related PH. (See
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2312821967">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Routine pulmonary and PH care
         </strong>
         – Patients with SAPH should exercise as tolerated, receive routine vaccinations  (
         <a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">
          figure 1
         </a>
         ), be counselled against smoking (and vaping), and maintain a normal body mass index. When indicated, they should also be treated with oxygen and diuretics.(See
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anticoagulation
         </strong>
         – We do
         <strong>
          not
         </strong>
         typically anticoagulate patients with SAPH unless another indication is present (eg, atrial fibrillation, chronic thromboembolic disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – We counsel females of childbearing age about the risks of pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rehabilitation
         </strong>
         – Cardiopulmonary rehabilitation is reasonable in those with indications (eg, severe dyspnea deconditioning). Rehabilitation has not been extensively studied in this population, but favorable responses have been noted in individual cases [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">
          "Pulmonary rehabilitation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3381341781">
         <span class="h2">
          Optimizing therapy for comorbidities
         </span>
         <span class="headingEndMark">
          —
         </span>
         We optimize therapies for any comorbidities known to be associated with or to worsen PH, particularly congestive heart failure, obstructive sleep apnea, obesity, and underlying lung disease, all of which are common in patients with SAPH [
         <a href="#rid4">
          4
         </a>
         ]. We provide guidance on nutrition and weight loss, if needed. Fluid volume management is particularly important in those with group 2 and group 5 PH phenotypes  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">
          "Obstructive sleep apnea: Overview of management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Optimized management of left heart disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2831464489">
         <span class="h1">
          SARCOIDOSIS-SPECIFIC THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoidosis-specific therapies are targeted at treating granulomatous inflammation, which is presumed to be driving the development and progression of PH.
        </p>
        <p class="headingAnchor" id="H3911405433">
         <span class="h2">
          Anti-inflammatory therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We assess patients with SAPH to determine the likelihood of response to anti-inflammatory therapy. For potentially responsive patients with SAPH, we perform a trial of new or escalating anti-inflammatory therapy rather than maintaining current therapy. We do not alter anti-inflammatory treatment for SAPH in those who are unlikely to be responsive.
        </p>
        <p class="headingAnchor" id="H3397149835">
         <span class="h3">
          Assessing potential responsiveness
         </span>
         <span class="headingEndMark">
          —
         </span>
         We consider patients potentially responsive to increased anti-inflammatory therapy if they have one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiographic features suggesting active granulomatous inflammation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of pulmonary vascular compression by granulomatous lesions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active inflammation (ie, uptake) on fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET)
        </p>
        <p>
        </p>
        <p>
         Patients who do not fulfill any of these criteria are considered
         <strong>
          unlikely
         </strong>
         to be responsive.
        </p>
        <p class="headingAnchor" id="H4173263695">
         <span class="h3">
          Agent selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anti-inflammatory agent selection varies among experts, but a trial of therapeutic escalation for 6 to 12 months is appropriate. Lack of response should prompt re-evaluation and likely de-escalation back to prior maintenance therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment-naive patients
         </strong>
         – When anti-inflammatory therapy is deemed appropriate and the patient is treatment naive, we suggest use of a tumor necrosis factor alpha (TNF-alpha) inhibitor (eg,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ) or, if that is not feasible, low-dose glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.1 to 0.2mg/kg/day) with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         for 6 to 12 months. While some experts use larger doses of glucocorticoids in treatment-naive patients (eg, prednisone 0.3 to 0.6 mg/kg/day for one month then taper), we prefer to avoid overexposure to higher doses of glucocorticoids consistent with treatment guidelines due to their cumulative negative adverse effects. (See
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach", section on 'Assessing disease severity and progression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients already receiving anti-inflammatory therapy
         </strong>
         – For patients already on anti-inflammatory therapy, we escalate immunosuppression (eg, add TNF-alfa inhibitor or add glucocorticoids to
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Once anti-inflammatory therapy is started or escalated, we initially follow these patients at 6 to 12 weeks to justify prolonged therapy for 6 to 12 months. Following-up with patients to determine the response to therapy is discussed below. (See
         <a class="local">
          'Monitoring and follow-up'
         </a>
         below.)
        </p>
        <p>
         Our approach is based upon our experience and limited data that suggest a possible benefit from anti-inflammatory therapy [
         <a href="#rid5">
          5-10
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 22 patients with SAPH and stage 2 or 3 sarcoidosis  (
         <a class="graphic graphic_table graphicRef56321" href="/z/d/graphic/56321.html" rel="external">
          table 2
         </a>
         ) on chest radiography, glucocorticoid therapy resulted in improvement in pulmonary hemodynamics at rest and during exercise [
         <a href="#rid7">
          7
         </a>
         ]. Similarly, in a separate study, only patients who did not have stage 4 disease demonstrated improvement with a 20 percent reduction in systolic pulmonary artery pressure (PAP) at six months based on echocardiography [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the French Pulmonary Hypertension Registry, 11 patients with mixed mechanisms for SAPH were treated with high-dose glucocorticoids, either alone or in combination with a secondary immunosuppressive agent [
         <a href="#rid10">
          10
         </a>
         ]. Compared with baseline, anti-inflammatory agents were associated with improvements in mean PAP (mPAP), peripheral vascular resistance, cardiac index, World Health Organization (WHO) functional class  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ), and six-minute walk distance. The best response was seen in patients who had extrinsic pulmonary artery compression from lymph nodes that were associated with increased activity on FDG-PET scan.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2056033681">
         <span class="h2">
          Antifibrotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effect of antifibrotic agents, such as
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         and
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         , on the course of SAPH has not been well studied and is not typically started unless indicated for sarcoidosis-related lung disease. (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3488411819">
         <span class="h1">
          PH PHENOTYPE-TARGETED THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H4019016642">
         <span class="h2">
          Assessing dominant phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with SAPH, we assess whether they have a dominant phenotype  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 1
         </a>
         ) and generally apply the same principles of management as for patients with that phenotype. This assessment is typically performed in the postdiagnostic setting using diagnostic investigations. Further details of this assessment are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/132051.html" rel="external">
          "Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults", section on 'Postdiagnostic testing and phenotyping'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'
         </a>
         .)
        </p>
        <p>
         While most patients with SAPH are classified as having group 5 PH, many patients have components of class 2 or 3 PH (or both) while a smaller proportion have class 4 disease. Patients with characteristics of group 1 pulmonary arterial hypertension (PAH) are rare [
         <a href="#rid11">
          11
         </a>
         ]. Consequently, most patients with SAPH are not candidates for PH-specific therapy, but they may be eligible to participate in trials. Data that describe the prevalence of dominant phenotypes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/132051.html" rel="external">
          "Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2539615453">
         <span class="h2">
          Avoidance of routine vasoreactivity testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do
         <strong>
          not
         </strong>
         routinely perform vasoreactivity testing unless the patient is thought to have a specific subtype of PAH (eg, idiopathic, heritable, or toxic-related PAH).
        </p>
        <p>
         This approach is based upon the low prevalence of the vasoreactive PAH phenotype in SAPH. Data on vasoreactivity in SAPH are limited and variable. While older retrospective studies reported a high incidence of vasoresponsiveness (eg, 11 to 18 percent decrease in mean pulmonary artery pressure [mPAP] and 31 to 45 percent decrease in peripheral vascular resistance [
         <a href="#rid12">
          12,13
         </a>
         ]), several newer studies reported acute vasoresponsiveness in less than 25 percent [
         <a href="#rid14">
          14,15
         </a>
         ], and our experience suggests that it is considerably lower (eg, &lt;5 percent). (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Vasoreactivity testing (select patients)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3588011545">
         <span class="h2">
          PH without a dominant phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no standard management strategy for patients who have mixed etiologies or patients without a dominant phenotype. Optimizing therapies for each potential phenotype contribution is reasonable. As examples, for patients with components of both cardiac- and pulmonary-related disease, we optimize therapy for left ventricular dysfunction and interstitial lung disease; patients with PAH-type physiology may be eligible for PAH-specific therapy in a clinical trial setting.
        </p>
        <p class="headingAnchor" id="H5261374">
         <span class="h2">
          PH with dominant cardiac and/or pulmonary contributions
         </span>
         <span class="headingEndMark">
          —
         </span>
         We manage patients who have PH with strong cardiac and/or pulmonary parenchymal phenotypes like patients with non-sarcoidosis-associated group 2 and 3 PH. Further details are provided in the following linked topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">
          "Management and prognosis of cardiac sarcoidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2564366975">
         <span class="h2">
          PH with vascular obstruction or thromboembolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with SAPH have PH due to extrinsic pulmonary vascular compression by intrathoracic lymphadenopathy or fibrosing mediastinitis or, more rarely, PH due to chronic thromboembolic disease (CTEPH).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extrinsic pulmonary vascular compression
         </strong>
         – PH due to extrinsic sarcoid masses may respond to anti-inflammatory therapy. (See
         <a class="local">
          'Anti-inflammatory therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an adjunct, we evaluate candidacy for local therapies such as percutaneous balloon pulmonary angioplasty (BPA) and/or stenting of the pulmonary vascular tree. These interventions have improved the mPAP and six-minute walk distance in a few patients with SAPH [
         <a href="#rid16">
          16-18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Percutaneous balloon pulmonary angioplasty'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with PH due to fibrosing mediastinitis may also respond to BPA/stenting, the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4397.html" rel="external">
          "Mediastinal granuloma and fibrosing mediastinitis", section on 'Symptomatic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CTEPH
         </strong>
         – CTEPH is rare in SAPH. The management of CTEPH with anticoagulation and evaluation for pulmonary endarterectomy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1254084670">
         <span class="h2">
          PH with dominant primary pulmonary vasculopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with SAPH have PH that is not explained by any etiology  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 1
         </a>
         ) and may share hemodynamic characteristics similar to PAH. While patients with
         <strong>
          non
         </strong>
         -sarcoidosis-related PAH are candidates for PAH-specific therapy (ie, treatment that targets arterial vasoconstriction and arteriopathy), patients with SAPH are not generally candidates for such therapy. PAH-specific therapy should only be prescribed in a specialized center and (in general) only in a trial setting or a case-by-case basis due to the potential for harm in patients with sarcoidosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Available PAH-specific therapies
         </strong>
         – The majority of the available PAH-specific therapies have been described in SAPH patients who are assessed to have a "PAH"-similar phenotype  (
         <a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">
          table 4
         </a>
         ). PH-specific agents include prostacyclin pathway agonists (eg,
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         ,
         <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">
          treprostinil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         ,
         <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">
          selexipag
         </a>
         ), endothelin receptor antagonists (eg,
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          bosentan
         </a>
         ,
         <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">
          macitentan
         </a>
         ,
         <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">
          ambrisentan
         </a>
         ), and nitric oxide-cyclic guanosine monophosphate enhancers (eg, phosphodiesterase [PDE] type 5 inhibitors
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         ,
         <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">
          tadalafil
         </a>
         ; soluble guanylate cyclase stimulator
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         ). Calcium channel blockers are not generally used in SAPH. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Vasoreactive patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If PAH-specific therapy is chosen outside of a trial setting on a case-by-case basis after discussion in a multidisciplinary meeting, sequential (eg, a PDE inhibitor, followed by a second oral agent one to two months later if initial therapy is tolerated) rather than upfront combination oral therapy is a safer approach. The treatment strategy is otherwise similar to that used in patients with non-sarcoidosis-related PAH, which is described separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Only limited data describe the use of PAH-specific therapies in patients with SAPH. Studies generally consist of small cohorts or single-arm clinical trials or small randomized trials. In addition, in most studies, PAH specific therapy was combined with anti-inflammatory therapy, rendering it difficult to distinguish the contribution of each therapy to the overall response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          bosentan
         </a>
         is the most commonly studied therapy [
         <a href="#rid15">
          15,19,20
         </a>
         ], other agents, including inhaled
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         , inhaled nitric oxide,
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">
          ambrisentan
         </a>
         ,
         <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">
          macitentan
         </a>
         ,
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         , or combination therapy, have shown improvements in functional capacity, quality of life, and hemodynamics [
         <a href="#rid9">
          9,10,12,13,15,19-31
         </a>
         ]. However, data are not consistent. In addition, most studies suggest that the benefit is marginal and some even report rare cases of pulmonary edema and worsening of hypoxemia (likely due to the coexistence of pulmonary veno-occlusive disease [PVOD]) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients with SAPH in whom decompensation is demonstrated following PAH-specific therapy (eg, worsening hypoxemia and/or pulmonary edema) should be re-evaluated for the possibility of PVOD/pulmonary capillary hemangiomatosis or for possible components of group 2/3 PH [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Special consideration may need to be given to a potential interaction between PAH-specific therapy and antifungals that may be used to treat fungal-related cavitary disease, which can be seen in patients with sarcoidosis.
        </p>
        <p class="headingAnchor" id="H799731171">
         <span class="h1">
          MONITORING AND FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         When left untreated, PH is progressive. Although there is no consensus, the following is our general approach to follow-up:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all patients with SAPH, every three to six months, we clinically monitor for worsening or improving symptoms of PH at every visit. This includes dyspnea, World Health Organization (WHO) functional class  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ), exercise tolerance (eg, six-minute walk distance), and symptoms of right heart failure that may suggest progression (eg, leg edema, syncope). (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with SAPH on anti-inflammatory therapy, we additionally obtain N-terminal pro-brain natriuretic peptide. We also perform echocardiography after six months of therapy. There is no consensus or set criteria on what constitutes a response to therapy. We use clinical judgement and results of testing to inform management.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those with SAPH who have worsening symptoms, we assess for PH progression using repeat echocardiography.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We also assess the potential contribution of other etiologies to worsening symptoms in the context of the predominant phenotype. For example, for those with primarily a group 3 phenotype, we would assess lung parenchyma with computed tomographic imaging and pulmonary function tests. With a group 2 phenotype, we would begin with repeat echocardiography and consider cardiac fluorine-18-fluorodeoxyglucose-positron emission tomography or magnetic resonance imaging based on the results.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In some cases, right heart catheterization may also be needed to evaluate disease progression after excluding other causes of progressive symptoms (eg, deteriorating interstitial lung disease, newly developed cardiac disease, anemia, atrial fibrillation, pulmonary embolism). (See
         <a class="local">
          'PH phenotype-targeted therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Echocardiography'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those with SAPH who improve or are stable on anti-inflammatory therapy, we typically continue treatment at the lowest effective dose and obtain periodic echocardiograms, the frequency of which is based upon clinical judgment (eg, every one to two years in stable patients) to reassess heart size, function, and pulmonary hemodynamics, although the value of this approach is unproven.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those receiving PH-specific therapy, we follow up using the same protocol as that outlined in patients with non-sarcoidosis-related pulmonary arterial hypertension, the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Follow-up'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3855351114">
         <span class="h1">
          REFRACTORY DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H816224259">
         <span class="h2">
          Organ transplant referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with SAPH who are refractory to therapy, lung or cardiac transplantation may be an option. PH does not influence candidacy for lung transplantation and outcomes appear to be no different than those in other patients undergoing lung transplantation. Further details regarding organ transplantation are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Refractory patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy", section on 'Lung transplantation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3528.html" rel="external">
          "Heart transplantation in adults: Indications and contraindications"
         </a>
         .)
        </p>
        <p>
         Patients with SAPH may also be eligible for a right-to-left shunt as a temporizing measure (eg, bridge to transplantation). Further details on this procedure are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Right-to-left shunt'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H453455998">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3032283947">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with sarcoidosis, SAPH is an independent risk factor for mortality [
         <a href="#rid10">
          10,33-36
         </a>
         ]. Multiple studies demonstrate a five-year mortality of approximately 35 to 45 percent [
         <a href="#rid5">
          5,10,33,34,37-39
         </a>
         ]. The hazard ratio for mortality due to SAPH ranges from 7.4 to 8.2 when compared with patients who have sarcoidosis, but do not have PH [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An analysis of patients with SAPH using the United Network for Organ Sharing database in 2005 showed that 27 percent died awaiting lung transplantation [
         <a href="#rid35">
          35
         </a>
         ]. In agreement, another study reported that among 43 patients with SAPH who were listed for lung transplantation, 53 percent died on the wait list [
         <a href="#rid40">
          40
         </a>
         ]; the mortality rates at one, two, and three years were 34, 60, and 69 percent, respectively. However, estimates since then have reported lower mortality rates of approximately 18 percent while awaiting lung transplantation [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another retrospective cohort study, one-, two-, and five-year mortality rates in 22 patients with SAPH were 15, 26, and 41 percent, respectively [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a two-year follow-up study of 130 patients with SAPH, the mortality rate of SAPH without left ventricular dysfunction was 36 percent [
         <a href="#rid37">
          37
         </a>
         ], 10-fold higher than the mortality rate for patients with sarcoidosis without PH [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The multinational SAPH registry, which includes only patients with precapillary PH, described a one-, three-, and five-year transplant-free survival rate of 89, 71, and 62 percent, respectively [
         <a href="#rid39">
          39
         </a>
         ]. The French SAPH registry, which included patients with severe precapillary PH (mean pulmonary artery pressure [mPAP] &gt;35 mmHg or mPAP 25 to 35 mmHg with cardiac index &lt;2.5 L/min/m
         <sup>
          2
         </sup>
         ) reported similar rates of survival at one year (93 percent), three years (74 percent), and five years (55 percent) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The impact of pulmonary arterial hypertension-specific or other therapies on quality of life, longevity, and mortality in SAPH is unknown.
        </p>
        <p class="headingAnchor" id="H1340116965">
         <span class="h2">
          Other outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of SAPH is associated with reduced exercise tolerance, increased supplemental oxygen requirement, increased need for help in activities of daily living, poorer quality of life, and higher likelihood of unemployment compared with sarcoidosis alone [
         <a href="#rid33">
          33,42
         </a>
         ]. Patients are seven times more likely to require supplemental oxygen if they develop SAPH [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2205903889">
         <span class="h2">
          Prognostic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognostic factors that have been associated with reduced survival in SAPH include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         World Health Organization (WHO) functional class IV  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiograph stage 4  (
         <a class="graphic graphic_table graphicRef56321" href="/z/d/graphic/56321.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid37">
          37,38
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced diffusing capacity for carbon monoxide &lt;35 percent predicted [
         <a href="#rid10">
          10,22,39
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Six-minute walk distance &lt;300 m [
         <a href="#rid10">
          10,39
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         mPAP &gt;35 mmHg without evidence of left ventricular dysfunction [
         <a href="#rid37">
          37,43
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased pulmonary vascular resistance (&gt;3 Wood units) [
         <a href="#rid22">
          22,37,43
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of right ventricular failure (eg, right atrial pressure &gt;15 mmHg) [
         <a href="#rid22">
          22,34,40
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3983784027">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
        </p>
        <p>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116637.html" rel="external">
          "Society guideline links: Sarcoidosis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">
          "Society guideline links: Pulmonary hypertension in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3969829607">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multidisciplinary approach
         </strong>
         – Treatment of sarcoidosis-associated pulmonary hypertension (SAPH) warrants a multidisciplinary approach at PH centers with experience in both PH and sarcoidosis. (See
         <a class="local">
          'Referral to expert center'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assess the potential for anti-inflammatory therapy
         </strong>
         – We initially determine the likelihood of PH response to anti-inflammatory therapy. For potentially responsive SAPH patients, we perform a trial of new or escalating anti-inflammatory therapy rather than no therapy or maintaining current therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Our approach is based upon our experience and limited data that suggest a possible benefit from anti-inflammatory therapy in this population. (See
         <a class="local">
          'Anti-inflammatory therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A potential response to anti-inflammatory therapy includes one or more of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Radiographic features suggesting active granulomatous inflammation
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Evidence of pulmonary vascular compression by granulomatous lesions
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Active inflammation on fluorine-18-fluorodeoxyglucose-positron emission tomography
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When anti-inflammatory therapy is chosen, we suggest addition of tumor necrosis factor alpha (TNF-alpha) inhibitor (eg,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ) rather than other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Low-dose glucocorticoids (eg, 0.1 to 0.2 mg/kg/day of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ) with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         is a reasonable alternative. These options minimize cumulative negative adverse effects of high-dose glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PH-phenotype-targeted therapy
         </strong>
         – For patients with SAPH, we assess whether a dominant phenotype is present  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 1
         </a>
         ). Further details of this assessment are provided separately. (See
         <a class="local">
          'PH phenotype-targeted therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/132051.html" rel="external">
          "Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults", section on 'Postdiagnostic testing and phenotyping'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally apply the same principles of management as for patients with that phenotype with the following SAPH-specific issues:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Avoidance of vasoreactivity testing
         </strong>
         – We do
         <strong>
          not
         </strong>
         routinely perform vasoreactivity testing since vasoreactive pulmonary arterial hypertension (PAH) is a rare occurrence in SAPH. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Vasoreactivity testing (select patients)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No dominant phenotype
         </strong>
         – There is no standard management strategy for patients who have mixed etiologies or no dominant etiology for their SAPH. Optimizing therapies for each contribution is reasonable. (See
         <a class="local">
          'PH without a dominant phenotype'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Contributions from concomitant cardiac and/or pulmonary parenchymal disease
         </strong>
         – We optimize therapy for contributing cardiopulmonary disease, which is discussed separately:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults", section on 'Management'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">
          "Management and prognosis of cardiac sarcoidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vascular obstruction or chronic venous thromboembolism
         </strong>
         – Patients with pulmonary vascular obstruction may respond to anti-inflammatory therapy and, in some cases, local interventions such as balloon pulmonary angioplasty and/or stenting. Patients with evidence of chronic thromboembolic disease may be evaluated for anticoagulation and/or pulmonary endarterectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Percutaneous balloon pulmonary angioplasty'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4397.html" rel="external">
          "Mediastinal granuloma and fibrosing mediastinitis", section on 'Symptomatic therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dominant primary pulmonary vasculopathy
         </strong>
         – For most patients with hemodynamic findings consistent with group 1 PAH, we suggest
         <strong>
          not
         </strong>
         prescribing PAH-specific therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Limited data in this population suggest possible harms including hypoxemia and pulmonary edema. However, on a case-by-case basis under the supervision of experts in a specialized center or in the context of a trial, PAH-specific therapy is sometimes administered; in such cases, sequential therapy (eg, a phosphodiesterase inhibitor, followed by a second oral agent in one to two months if initial therapy is tolerated) rather than upfront combination oral therapy is a safer approach. (See
         <a class="local">
          'PH with dominant primary pulmonary vasculopathy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring and follow-up
         </strong>
         – For all patients with SAPH, every three to six months we clinically assess symptoms, World Health Organization (WHO) functional class  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ), and exercise tolerance (eg, six-minute walk distance).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with SAPH on anti-inflammatory therapy, we additionally obtain N-terminal pro-brain natriuretic peptide levels and also perform echocardiography after six months of therapy. We use clinical judgement and results of testing to inform the decision to manage therapy. For those who respond or stabilize with anti-inflammatory therapy, we typically continue treatment at the lowest effective dose while in those with worsening symptoms, we assess for PH progression and the potential contribution of other etiologies (See
         <a class="local">
          'Monitoring and follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those receiving PH-specific therapy, we follow up using the same protocol as that outlined in patients with non-sarcoidosis-related PAH, the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Follow-up'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with SAPH who are refractory to therapy, lung or cardiac transplantation may be an option. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Refractory patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy", section on 'Lung transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis of SAPH is poor. In patients with sarcoidosis, SAPH is an independent risk factor for mortality. Five-year mortality rates are approximately 35 to 45 percent, with the highest rates in those awaiting lung transplantation. The impact of therapy on quality of life, longevity, and mortality is unknown. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201:e26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savale L, Huitema M, Shlobin O, et al. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev 2022; 31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrera-Olivares AM, García-Manso JM, Rodríguez-Gómez I, et al. Long-Term Benefits of Tailored Exercise in Severe Sarcoidosis: A Case Report. Int J Environ Res Public Health 2020; 17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcellis RG, Lenssen AF, de Vries J, Drent M. Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. Curr Opin Pulm Med 2013; 19:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies J, Nellen M, Goodwin JF. Reversible pulmonary hypertension in sarcoidosis. Postgrad Med J 1982; 58:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gluskowski J, Hawrylkiewicz I, Zych D, Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990; 97:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sumimoto K, Taniguchi Y, Emoto N, Hirata KI. Combination therapy with pulmonary arterial hypertension targeted drugs and immunosuppression can be a useful strategy for sarcoidosis-associated pulmonary hypertension: a case report. Eur Heart J Case Rep 2021; 5:ytaa454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathijssen H, Huitema MP, Bakker ALM, et al. Clinical Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension. Heart Lung Circ 2021; 30:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Shlobin OA, Wells AU, et al. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respir Med 2018; 139:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milman N, Svendsen CB, Iversen M, et al. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil. Clin Respir J 2009; 3:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton-Craig CR, Slaughter R, McNeil K, et al. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ 2009; 18:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           daSilva-deAbreu A, Bracamonte-Baran W, Condado JF, et al. Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis-Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis. Curr Probl Cardiol 2021; 46:100616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labyk A, Wretowski D, Zybińska-Oksiutowicz S, et al. Balloon pulmonary angioplasty - efficient therapy of chronic thromboembolic pulmonary hypertension in the patient with advanced sarcoidosis - a case report. BMC Pulm Med 2018; 18:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judson MA, Highland KB, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathijssen H, Huitema MP, Bakker ALM, et al. Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abston E, Hon S, Lawrence R, et al. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keir GJ, Walsh SL, Gatzoulis MA, et al. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest 2015; 148:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007; 9 Suppl 2:S8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro S, Pollock DM, Gillies H, et al. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol 2012; 110:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford HJ, Baughman RP, Aris R, et al. Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. Pulm Circ 2016; 6:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Shlobin OA, Gupta R, et al. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial. Chest 2022; 161:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abston E, Moll M, Hon S, et al. Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duong H, Bonham CA. Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment. Clin Pulm Med 2018; 25:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huitema MP, Mathijssen H, Mager JJ, et al. Sarcoidosis-Associated Pulmonary Hypertension. Semin Respir Crit Care Med 2020; 41:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobarro D, Schreiber BE, Handler C, et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 2013; 111:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nardi A, Brillet PY, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shlobin OA, Kouranos V, Barnett SD, et al. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J 2020; 55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gangemi AJ, Myers CN, Zheng M, et al. Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: Experience from a high volume center. Respir Med 2019; 157:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Engel PJ, Nathan S. Pulmonary Hypertension in Sarcoidosis. Clin Chest Med 2015; 36:703.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 138414 Version 1.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32293205" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35140103" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33353138" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Long-Term Benefits of Tailored Exercise in Severe Sarcoidosis: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23851328" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16227329" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7111113" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Reversible pulmonary hypertension in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2365034" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2298084" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33554014" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Combination therapy with pulmonary arterial hypertension targeted drugs and immunosuppression can be a useful strategy for sarcoidosis-associated pulmonary hypertension: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29051269" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33933365" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11555522" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17099027" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29858005" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20298406" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378190" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32532452" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Characteristics and Outcomes of Pulmonary Angioplasty With or Without Stenting for Sarcoidosis-Associated Pulmonary Hypertension: Systematic Review and Individual Participant Data Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30115061" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Balloon pulmonary angioplasty - efficient therapy of chronic thromboembolic pulmonary hypertension in the patient with advanced sarcoidosis - a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22117505" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Ambrisentan for sarcoidosis associated pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33093771" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33093789" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25078636" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118270" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26437815" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17767746" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pulmonary hypertension associated with sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20560291" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Inhaled iloprost for sarcoidosis associated pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24177203" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22858181" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28090299" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Tadalafil therapy for sarcoidosis-associated pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34363816" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33093782" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30294198" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32777851" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Sarcoidosis-Associated Pulmonary Hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23290599" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970018" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Predicting mortality in patients with sarcoidosis awaiting lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24503267" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20348196" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22075486" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Stage IV sarcoidosis: comparison of survival with the general population and causes of death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32139456" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11555523" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31522032" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: Experience from a high volume center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15863633" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26593143" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pulmonary Hypertension in Sarcoidosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
